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In the early 1990s, IVUS was used as a tool to assess the efficacy of percutaneous cardiac interventions, specifically the seating of coronary stents. As it was found to assess coronary intimal thickening, it was used in heart transplantation patients because they could develop rapidly progressive intimal thickening in the first year after transplantation. Further studies led to its use as a prognostic tool. Several studies demonstrated that first-year IVUS findings had significantly more intimal thickening (compared with ensuing years) (2), which was believed to be due to an initial heightened immune response to the donor heart (3).
Because increased intimal thickening in the first year after transplantation was thought to be harmful to the donor heart, first-year IVUS was evaluated as a possible biomarker for poor outcome. From the Cedars-Sinai Heart Institute, Los Angeles, California. Dr.
Kobashigawa is scientific medical advisor to TransMedics Inc. and Novartis; and has received research grants and research support from Novartis, CareDx Inc., and TransMedics Inc. It is not surprising that other IVUS parameters in the current era of heart transplantation may be even more sensitive as a marker for poor outcome after heart transplantation due to advances in the field.
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